74313
document
Flow-cytometric studies with eleutherococcus senticosus extract as an immunomodulatory agent . A placebo-controlled study of the effect of an Eleutherococcus senticosus extract ( Eleukokk ) on the immune system was performed with 36 healthy volunteers utilising quantitative multi-parameter flow cytometry with monoclonal antibodies directed against specific surface markers of human lymphocyte subsets . Volunteers in the verum group received 10 ml of an ethanolic ( vincamine free ) eleutherococcus senticosus preparation , 3 times daily for 4 weeks . In the placebo , the eleutherococcus extract was substituted by additional wine , resulting in identical final concentrations of ethanol in both preparations . The purpose of the double-blind study was the demonstration of possible effects on the cellular immune status , as determined by quantitative flow cytometry . The most salient feature in the verum group was a drastic increase in the absolute number of immunocompetent cells , with an especially pronounced effect on T lymphocytes , predominantly of the helper/inducer type , but also on cytotoxic and natural killer cells . In addition , a general enhancement of the activation state of T lymphocytes was observed . No side effects were observed during the trial or afterwards ( observation period 6 months ) .
74314
Intervention_Educational
eleutherococcus senticosus extract
74315
Intervention_Control
placebo-controlled
74316
Intervention_Educational
Eleutherococcus senticosus extract ( Eleukokk )
74317
Intervention_Control
placebo , the eleutherococcus extract was substituted by additional wine , resulting in identical final concentrations of ethanol in both preparations
74318
Outcome_Physical
cellular immune status
74319
Outcome_Other
quantitative flow cytometry
74320
Outcome_Physical
absolute number of immunocompetent cells
74321
Outcome_Physical
T lymphocytes
74322
Outcome_Physical
helper/inducer type
74323
Outcome_Physical
cytotoxic and natural killer cells .
74324
Outcome_Physical
activation state of T lymphocytes
74325
Outcome_Adverse-effects
side effects
74326
Participant_Condition
immune system
74327
Participant_Sample-size
36